• Queens University at Kingston
• Research St. Joseph's - Hamilton (RSJ-H)
• Sinai Health System (SHS) (formerly Mount Sinai Hospital (MSH))
• Sunnybrook Research Institute (SRI)
• The Hospital for Sick Children (SickKids)
• Thunder Bay Regional Health Sciences Centre (TBRHSC)
• Trillium Health Partners
• Unity Health Toronto (comprised of Providence Healthcare, St. Joseph's Health Centre and St. Michael's Hospital)
• University Health Network (UHN)
• University of Guelph
• University of New Brunswick
• University of Ottawa
• University of Toronto (UofT)
• University of Waterloo
• University of Western Ontario, London
• University of Windsor
• Vitalite Health Network (New Brunswick Regional Health Authority)
• William Osler Health System
• Women's College Hospital
• York University (data only)
• Baycrest Health Sciences (Baycrest Centre for Geriatric Care, Baycrest Hospital, The Baycrest Day Care Centre, The Jewish Home for the Aged)
• Carleton University
• Centre for Addiction & Mental Health (CAMH)
• Hamilton Health Sciences Corporation
• Holland Bloorview Kids Rehabilitation Hospital (HBK)
• Kingston Health Sciences Centre
• Laurentian University
• Lawson Health Research Institute
• McMaster University
• Michael Garron Hospital, Toronto East Health Network
• Montfort Hospital
• North York General Hospital
• Oak Valley Health (comprised of Markham Stouffville Hospital and Uxbridge Hospital) – signatures pending
• Ontario Agency for Health and Promotion (Public Health Ontario)
• Ontario Institute for Cancer Research (OICR)
• Ottawa Hospital Research Institute (OHRI)
• Ontario Tech University
• Provincial Health Services Authority BC
• BC Cancer, BC Centre for Disease Control, and BC Children’s and Women’s Hospital
Inaugural in 2024, this exclusive event will bring together life science industry leaders and investors to learn about the latest initiatives, resources, innovations and partnership opportunities within Canada’s leading research hospital and medical commercialization centre – University Health Network.
Available by invitation only, this showcase will introduce UHN's new Accelerator Fund and will feature commercially viable and investment-ready life science opportunities from our hospitals and research institutes.
Hear the latest developments directly from our researchers and spin-out companies, which are leading the charge of cutting-edge biomedical discoveries with potential to change patients' lives. You’ll also hear about the leading resources and expertise that UHN can deploy for risk-sharing partnerships.
Questions about the event? Please email robert.foldes(at)uhn.ca or ania.jones(at)uhn.ca
• Dr. Gordon Keller, McEwen Stem Cell Institute – “Novel revascularization cell therapy”
• Dr. Paul Bradshaw, CEO, Inteligex
• Dr. Sarah Crome, Toronto General Hospital Research Institute – “Moving tolerogenic ILC therapy towards the clinic”
• Dr. Shinichiro Ogawa, McEwen Stem Cell Institute – “Composite liver tissue utilizing 3D bioprinting for sustainable engraftment to treat liver diseases”
• Dr. Pamela Ohashi, Princess Margaret Cancer Centre –“Improving cell-based immunotherapy"
• Dr. Trevor Pugh, Princess Margaret Cancer Centre - "CapTCR/IG-seq: Immune repertoire sequencing for cancer diagnosis, monitoring, and interpreting immunotherapy response"
• Dr. Andrew Sage, Toronto General Hospital Research Institute – "Harnessing ex vivo organ perfusion for the creation of digital lungs"
• Dr. Bo Wang, Chief AI Scientist at UHN - "AI Hub at UHN"
• Dr. Michael Brudno, Chief Data Scientist, UHN – "Mayo Clinic Platform Connect collaboration"
• Dr. Phedias Diamandis, Princess Margaret Cancer Centre – "PHAROAH - global crowdsourcing platform for computational pathology"
• Kirk Fergusson, CEO, Medly
• Steve Chackowicz, CEO, Curait Medical
• Dr. Anton Neschadim, CEO, Nanovista
• Douad Shah, VP Clinical Partnerships, Altis Labs
• Dr. Luke Brzozowski, Executive Director, Translational Research & Core Facilities
• Dr. Naz Chaudary, Manager, STTARR (Spatio-Temporal Targeting and Amplification of Radiation Response) Centre
• Dr. Harriet Feilotter, Division Head, Genome Diagnostics (Advanced Molecular Diagnostics Laboratory)
• Heidi Wagner, Head of Operations, UHN Biospecimen Services
• Jimmy Qiu, Manager, Engineering (TECHNA)
• José Mangles, Director of Operations, Cell/Vector Production Centre (CCVP)
• Wayne Ho, Managing Director, Healthcare Human Factors
• Julia Publicover, Director, Translational Research and Innovation – Quantitative Imaging for Personalized Cancer Medicine
• Dr. Amit Oza, CEO and Jacqueline Amaral, COO, Ozmosis Research Inc., UHN
• Dr. Sophia Yue Li, Staff Scientist & Strategic Partnerships Manager, The KITE Research Institute
• Dr. Milos Popovic, Director, The KITE Research Institute
• Dr. Alexandra Easson, Princess Margaret Cancer Centre - "Mosquito bite needle endoscopy"
• Dr. Darren Kraemer, CEO, Point Surgical - "10 second tumor biopsy"
• Dr. Rick Mangat, CEO, Traferox Technologies Inc. -" Ex-Vivo Organ Technologies"
• Dr. Olivia Sobczyk, Research Director, Thornhill Medical
• Anil Amlani, CEO, Moleculight
• Dr. Linda Penn, Princess Margaret Cancer Centre – “Targeting MYC oncoprotein activity for cancer therapy”
• Nigel Degruyther, EIR, Enesar – “Dantrolene reformulation for ventricular tachycardia”
• Dr. Mohammad Ali Amini, CEO, QurCan Therapeutics –"Breakthrough therapeutics enabled by a novel next generation nanoparticle platform"
• Dr. Natalie Galant, CEO, Paradox Immunotherapeutics – "Reshaping the future of protein misfolding diseases"
•Dr. Stephen Juvet, Scientist, Toronto General Hospital Research Institute (TGHRI) - Veritas Therapeutics
• Dr. Scott Bratman, Chief Innovation Officer, Adela Bio
• Steven Chackowicz, CEO, Curait Medical
• Nigel Degruyther, EIR, Enesar
• Dr. Paul Bradshaw, CEO, Inteligex
• Dr. Anton Neschadim, CEO, Nanovista
• Kirk Fergusson, CEO, Medly
• Dr. Natalie Galant, CEO, Paradox Immunotherapeutics
• Dr. Darren Kraemer, CEO, Point Surgical
• Dr. Mohammad Ali Amini, CEO, QurCan Therapeutics
• Dr. Rick Mangat, CEO, Traferox Technologies
• Dr. Olivia Sobczyk, Research Director, Thornhill Medical
• Anil Amlani, CEO, Moleculight
For more information, visit Our Companies and New Ventures.
The Accelerator Fund offers significant capital to help early-stage technologies advance. The fund is designed to expedite the promise of innovations within UHN and partner organizations to get them to patients faster. This fund will help those who need the funding to enhance their commercial potential and bring new medical products, devices, and therapies to the market more swiftly.
Learn More